Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia

Cristina Santoro; Isabella Sperduti; Roberto Latagliata; Erminia Baldacci; Barbara Anaclerico; Giuseppe Avvisati; Massimo Breccia; Francesco Buccisano; Michele Cedrone; Giuseppe Cimino; Cinzia De Gregoris; Marianna De Muro; Ambra Di Veroli; Sabrina Leonetti Crescenzi; Marco Montanaro; Enrico Montefusco; Raffaele Porrini; Angela Rago; Antonio Spadea; Francesca Spirito; Nicoletta Villivà; Alesssandro Andriani; Giuliana Alimena; Maria Gabriella Mazzucconi

doi:10.1002/cam4.1081

Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia

Cristina Santoro, Isabella Sperduti, Roberto Latagliata, Erminia Baldacci, Barbara Anaclerico, Giuseppe Avvisati, Massimo Breccia, Francesco Buccisano, Michele Cedrone, Giuseppe Cimino, Cinzia De Gregoris, Marianna De Muro, Ambra Di Veroli, Sabrina Leonetti Crescenzi, Marco Montanaro, Enrico Montefusco, Raffaele Porrini, Angela Rago, Antonio Spadea, Francesca SpiritoNicoletta Villivà, Alesssandro Andriani, Giuliana Alimena, Maria Gabriella Mazzucconi

Istituto Regina Elena

Research output: Contribution to journal › Article › peer-review

Abstract

Aim of this study is to explore the role of different treatments on the development of secondary malignancies (SMs) in a large cohort of essential thrombocythemia (ET) patients. We report the experience of a regional cooperative group in a real-life cohort of 1026 patients with ET. We divided our population into five different groups: group 0, no treatment; group 1, hydroxyurea (HU); group 2, alkylating agents (ALK); group 3, ALK + HU sequentially or in combination; and group 4, anagrelide (ANA) and/or α-interferon (IFN) only. Patients from groups 1, 2, and 3 could also have been treated either with ANA and/or IFN in their medical history, considering these drugs not to have an additional cytotoxic potential. In all, 63 of the 1026 patients (6%) developed 64 SM during the follow-up, after a median time of 50 months (range: 2-158) from diagnosis. In univariate analysis, a statistically significant difference was found only for gender (P = 0.035) and age (P = 0.0001). In multivariate analysis, a statistically significant difference was maintained for both gender and age (gender HR1.7 [CI 95% 1.037-2.818] P = 0.035; age HR 4.190 [CI 95% 2.308-7.607] P = 0.0001). The impact of different treatments on SMs development was not statistically significant. In our series of 1026 ET patients, diagnosed and followed during a 30-year period, the different therapies administered, comprising HU and ALK, do not appear to have impacted on the development of SM. A similar rate of SMs was observed also in untreated patients. The only two variables which showed a statistical significance were male gender and age >60 years.

Original language	English
Pages (from-to)	1233-1239
Number of pages	7
Journal	Cancer Medicine
Volume	6
Issue number	6
DOIs	https://doi.org/10.1002/cam4.1081
Publication status	Published - Jun 2017

Keywords

Journal Article

Access to Document

10.1002/cam4.1081

Cite this

Santoro, C., Sperduti, I., Latagliata, R., Baldacci, E., Anaclerico, B., Avvisati, G., Breccia, M., Buccisano, F., Cedrone, M., Cimino, G., De Gregoris, C., De Muro, M., Di Veroli, A., Leonetti Crescenzi, S., Montanaro, M., Montefusco, E., Porrini, R., Rago, A., Spadea, A., ... Mazzucconi, M. G. (2017). Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia. Cancer Medicine, 6(6), 1233-1239. https://doi.org/10.1002/cam4.1081

Santoro, C, Sperduti, I, Latagliata, R, Baldacci, E, Anaclerico, B, Avvisati, G, Breccia, M, Buccisano, F, Cedrone, M, Cimino, G, De Gregoris, C, De Muro, M, Di Veroli, A, Leonetti Crescenzi, S, Montanaro, M, Montefusco, E, Porrini, R, Rago, A, Spadea, A, Spirito, F, Villivà, N, Andriani, A, Alimena, G & Mazzucconi, MG 2017, 'Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia', Cancer Medicine, vol. 6, no. 6, pp. 1233-1239. https://doi.org/10.1002/cam4.1081

@article{63f92524934e4508bfaa2164d7996a35,

title = "Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia",

abstract = "Aim of this study is to explore the role of different treatments on the development of secondary malignancies (SMs) in a large cohort of essential thrombocythemia (ET) patients. We report the experience of a regional cooperative group in a real-life cohort of 1026 patients with ET. We divided our population into five different groups: group 0, no treatment; group 1, hydroxyurea (HU); group 2, alkylating agents (ALK); group 3, ALK + HU sequentially or in combination; and group 4, anagrelide (ANA) and/or α-interferon (IFN) only. Patients from groups 1, 2, and 3 could also have been treated either with ANA and/or IFN in their medical history, considering these drugs not to have an additional cytotoxic potential. In all, 63 of the 1026 patients (6%) developed 64 SM during the follow-up, after a median time of 50 months (range: 2-158) from diagnosis. In univariate analysis, a statistically significant difference was found only for gender (P = 0.035) and age (P = 0.0001). In multivariate analysis, a statistically significant difference was maintained for both gender and age (gender HR1.7 [CI 95% 1.037-2.818] P = 0.035; age HR 4.190 [CI 95% 2.308-7.607] P = 0.0001). The impact of different treatments on SMs development was not statistically significant. In our series of 1026 ET patients, diagnosed and followed during a 30-year period, the different therapies administered, comprising HU and ALK, do not appear to have impacted on the development of SM. A similar rate of SMs was observed also in untreated patients. The only two variables which showed a statistical significance were male gender and age >60 years.",

keywords = "Journal Article",

author = "Cristina Santoro and Isabella Sperduti and Roberto Latagliata and Erminia Baldacci and Barbara Anaclerico and Giuseppe Avvisati and Massimo Breccia and Francesco Buccisano and Michele Cedrone and Giuseppe Cimino and {De Gregoris}, Cinzia and {De Muro}, Marianna and {Di Veroli}, Ambra and {Leonetti Crescenzi}, Sabrina and Marco Montanaro and Enrico Montefusco and Raffaele Porrini and Angela Rago and Antonio Spadea and Francesca Spirito and Nicoletta Villiv{\`a} and Alesssandro Andriani and Giuliana Alimena and Mazzucconi, {Maria Gabriella}",

note = "{\textcopyright} 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.",

year = "2017",

month = jun,

doi = "10.1002/cam4.1081",

language = "English",

volume = "6",

pages = "1233--1239",

journal = "Cancer Medicine",

issn = "2045-7634",

publisher = "John Wiley and Sons Ltd",

number = "6",

}

TY - JOUR

T1 - Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia

AU - Santoro, Cristina

AU - Sperduti, Isabella

AU - Latagliata, Roberto

AU - Baldacci, Erminia

AU - Anaclerico, Barbara

AU - Avvisati, Giuseppe

AU - Breccia, Massimo

AU - Buccisano, Francesco

AU - Cedrone, Michele

AU - Cimino, Giuseppe

AU - De Gregoris, Cinzia

AU - De Muro, Marianna

AU - Di Veroli, Ambra

AU - Leonetti Crescenzi, Sabrina

AU - Montanaro, Marco

AU - Montefusco, Enrico

AU - Porrini, Raffaele

AU - Rago, Angela

AU - Spadea, Antonio

AU - Spirito, Francesca

AU - Villivà, Nicoletta

AU - Andriani, Alesssandro

AU - Alimena, Giuliana

AU - Mazzucconi, Maria Gabriella

PY - 2017/6

Y1 - 2017/6

N2 - Aim of this study is to explore the role of different treatments on the development of secondary malignancies (SMs) in a large cohort of essential thrombocythemia (ET) patients. We report the experience of a regional cooperative group in a real-life cohort of 1026 patients with ET. We divided our population into five different groups: group 0, no treatment; group 1, hydroxyurea (HU); group 2, alkylating agents (ALK); group 3, ALK + HU sequentially or in combination; and group 4, anagrelide (ANA) and/or α-interferon (IFN) only. Patients from groups 1, 2, and 3 could also have been treated either with ANA and/or IFN in their medical history, considering these drugs not to have an additional cytotoxic potential. In all, 63 of the 1026 patients (6%) developed 64 SM during the follow-up, after a median time of 50 months (range: 2-158) from diagnosis. In univariate analysis, a statistically significant difference was found only for gender (P = 0.035) and age (P = 0.0001). In multivariate analysis, a statistically significant difference was maintained for both gender and age (gender HR1.7 [CI 95% 1.037-2.818] P = 0.035; age HR 4.190 [CI 95% 2.308-7.607] P = 0.0001). The impact of different treatments on SMs development was not statistically significant. In our series of 1026 ET patients, diagnosed and followed during a 30-year period, the different therapies administered, comprising HU and ALK, do not appear to have impacted on the development of SM. A similar rate of SMs was observed also in untreated patients. The only two variables which showed a statistical significance were male gender and age >60 years.

AB - Aim of this study is to explore the role of different treatments on the development of secondary malignancies (SMs) in a large cohort of essential thrombocythemia (ET) patients. We report the experience of a regional cooperative group in a real-life cohort of 1026 patients with ET. We divided our population into five different groups: group 0, no treatment; group 1, hydroxyurea (HU); group 2, alkylating agents (ALK); group 3, ALK + HU sequentially or in combination; and group 4, anagrelide (ANA) and/or α-interferon (IFN) only. Patients from groups 1, 2, and 3 could also have been treated either with ANA and/or IFN in their medical history, considering these drugs not to have an additional cytotoxic potential. In all, 63 of the 1026 patients (6%) developed 64 SM during the follow-up, after a median time of 50 months (range: 2-158) from diagnosis. In univariate analysis, a statistically significant difference was found only for gender (P = 0.035) and age (P = 0.0001). In multivariate analysis, a statistically significant difference was maintained for both gender and age (gender HR1.7 [CI 95% 1.037-2.818] P = 0.035; age HR 4.190 [CI 95% 2.308-7.607] P = 0.0001). The impact of different treatments on SMs development was not statistically significant. In our series of 1026 ET patients, diagnosed and followed during a 30-year period, the different therapies administered, comprising HU and ALK, do not appear to have impacted on the development of SM. A similar rate of SMs was observed also in untreated patients. The only two variables which showed a statistical significance were male gender and age >60 years.

KW - Journal Article

U2 - 10.1002/cam4.1081

DO - 10.1002/cam4.1081

M3 - Article

C2 - 28544749

SN - 2045-7634

VL - 6

SP - 1233

EP - 1239

JO - Cancer Medicine

JF - Cancer Medicine

IS - 6

ER -

Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia

Abstract

Keywords

Access to Document

Fingerprint

Cite this